← Return to Bone turnover markers (CTX and P1NP): do you have a baseline?
DiscussionBone turnover markers (CTX and P1NP): do you have a baseline?
Osteoporosis & Bone Health | Last Active: Sep 20 11:58am | Replies (240)Comment receiving replies
Replies to "Tymlos versus Forteo? Is there data on which of these drugs gets better results ? My..."
The ACTIVE trial compared Tymlos (abaloparatide) and Forteo (teriparatide):
https://jamanetwork.com/journals/jama/fullarticle/2544640
Tymlos showed significantly greater gains than Forteo at the total hip and femoral neck. At the spine, both drugs worked well, but the difference between them wasn’t statistically significant. Some have pointed out that this wasn’t a true head-to-head study because it wasn’t fully double-blind for the two drugs.
For fracture outcomes (primary outcome), both reduced risk a lot compared with placebo, and there wasn’t a statistically significant difference between the two drugs.
Since they act in very similar ways, switching from Tymlos to Forteo may not lead to a dramatically different result, imo.
I know it’s discouraging not to see gains so far. Most people do respond in the first year, but there’s a small group (5–15% I’ve read) who don’t show much change. Sometimes it’s just that bone is responding in ways DXA doesn’t fully capture, or it may take longer. It can also help to check vitamin D blood levels, calcium intake, and rule out other possible reasons the medicine might not be working as expected.